// App-Quantinova.ai

4500 : Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426

Researchers

Presenter

  • Brian I. Rini

Principal Investigators

  • Viktor Stus

  • Tom Waddell

  • Rustem Gafanov

  • Frdric Pouliot

  • Dmitry Nosov

  • Bohuslav Melichar

  • Denis Soulieres

  • Delphine Borchiellini

  • Ihor O. Vynnychenko

  • Raymond S. McDermott

  • Sergio Jobim Azevedo

  • Satoshi Tamada

  • Anna Kryzhanivska

  • Chenxiang Li

  • Joseph E. Burgents

  • L. Rhoda Molife

  • Jens Bedke

  • Thomas Powles

Medical Centers

  • Vanderbilt-Ingram Cancer Center, Nashville, TN, Fox Chase Cancer Center, Philadelphia, PA, Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine

  • Dnipro, Ukraine

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Russian Research Centre of Roentgenoradiology, Moscow, Russia

  • CHU of Québec and Laval University, Québec City, ON, Canada

  • Central Clinical Hospital With Outpatient Clinic, Moscow, Russian Federation

  • Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada

  • Centre Antoine Lacassagne, Universite Cote dAzu, Nice, France

  • Sumy State University, Sumy Regional Clinical Oncology Center, Sumy, Ukraine

  • Adelaide and Meath Hospital and Trinity College Dublin, Dublin, Ireland

  • Hospital De Clinicas de Porto Alegre, Porto Alegre RS, Brazil

  • Kinki University, Osaka, Japan

  • Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine

  • Merck & Co., Inc., Kenilworth, NJ, MSD UK, London, United Kingdom

  • Eberhard-Karls-Universitaet Tuebingen, Tuebingen, Germany

  • Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • United States

  • Ukraine

  • United Kingdom

  • Russia

  • Canada

  • France

  • Ireland

  • Brazil

  • Japan

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Sunitinib

  • Inlyta

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02853331

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved